公开(公告)号：US20160367546A1

公开(公告)日：2016-12-22

申请号：US14744042

申请日：2015-06-19

Applicant: Macau University of Science and Technology

Inventor： Xiao Jun YAO ,  Lai Han LEUNG ,  Lian Xiang LUO ,  Yan Ling ZHOU ,  Liang LIU

IPC: A61K31/4745

CPC classification number: A61K31/4745

Abstract: The present invention provides a compound that inhibits activity of oncogenic ROS1, a composition comprising said compound. The present invention also provides the use of said composition for treating cancer.

Abstract translation: 本发明提供抑制致癌ROS1活性的化合物，其是包含所述化合物的组合物。 本发明还提供了所述组合物用于治疗癌症的用途。

公开(公告)号：US20150133492A1

公开(公告)日：2015-05-14

申请号：US14526539

申请日：2014-10-29

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Zhi Hong JIANG ,  Liang LIU ,  Wai Kit CHAN ,  Xiao Jun YAO

IPC: A61K31/4725

CPC classification number: A61K31/4725

Abstract: This invention is directed to the use of N-desmethyldauricine, a novel autophagy enhancer, in treating cancers or neurodegenerative conditions.

Abstract translation: 本发明涉及一种新型自噬增强剂N-去甲基牛磺酸在治疗癌症或神经变性疾病中的应用。

公开(公告)号：US20190175553A1

公开(公告)日：2019-06-13

申请号：US16257018

申请日：2019-01-24

Applicant: Macau University of Science and Technology

Inventor： Xiao Jun YAO ,  Lai Han Elaine LEUNG ,  Liang LIU ,  Qian Qian WANG ,  Jia Hui XU ,  Ying LI

IPC: A61K31/4045 ,  A61K45/06 ,  G01N33/574 ,  A61P35/00

Abstract: One embodiment is a method of treating cancer. The method includes administering a therapeutically effective amount of a compound to a patient. The compound is represented by Formula I:

公开(公告)号：US20190175526A1

公开(公告)日：2019-06-13

申请号：US15839883

申请日：2017-12-13

Applicant: Macau University of Science and Technology

Inventor： Xiao Jun YAO ,  Lai Han Elaine LEUNG ,  Liang LIU ,  Jia Hui XU ,  Qian Qian WANG ,  Ying LI

IPC: A61K31/136 ,  A61P35/00 ,  G01N33/574

Abstract: One embodiment relates to a method of treating cancer by administering a compound of Formula I to a patient. Another embodiment relates to a method of treating cancer with overexpressed protein arginine methyltransferases that includes administering to a patient the compound represented by the Formula I: